Review Article

Extracorporeal Shock Wave Therapy for the Treatment of Osteoarthritis: A Systematic Review and Meta-Analysis

Lu Chen, Ling Ye, Hui Liu, Pingliang Yang, and Bangxiang Yang

1Department of Pain Management, West China Hospital, Sichuan University, Chengdu 610041, China
2Department of Anesthesiology, The First Affiliated Hospital of Chengdu Medical College, Xindu, Sichuan 610500, China

Correspondence should be addressed to Ling Ye; zerodq_hx@163.com and Pingliang Yang; pingliangyang@163.com

Received 13 January 2020; Accepted 22 February 2020

Copyright © 2020 Lu Chen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Osteoarthritis is the most common musculoskeletal disease. Extracorporeal shockwave therapy had shown an effect on osteoarthritis in both some animal experiments and clinical studies, but there was no systematic review to confirm the value of shockwave therapy in the treatment of all types of osteoarthritis and compare it with other traditional therapies (especially traditional Chinese medicine).

Method. PubMed, Medline, the Cochrane Central Register of Controlled Trials, Web of Science, Chinese National Knowledge Infrastructure, WANFANG database, and VIP database were searched up to December 10, 2019, to identify randomized controlled trials comparing shockwave therapy and other treatments for osteoarthritis. Visual analogue scale and the Western Ontario and McMaster Universities Osteoarthritis Index were extracted and analyzed by RevMan and STATA software as outcomes of pain reduction and functional improvement. Adverse reactions were recorded to evaluate the safety of shockwave therapy.

Results. Shockwave therapy had significant improvement in both pain reduction and functional improvement compared with placebo, corticosteroid, hyaluronic acid, medication, and ultrasound ($P < 0.05$). In functional improvement, shockwave therapy showed statistical improvement compared with kinesiotherapy and moxibustion ($P < 0.05$) but not with acupotomy surgery ($P = 0.24$). A significant difference between shockwave therapy and platelet-rich plasma was observed in pain reduction ($P < 0.05$) but not in functional improvement ($P = 0.89$). Meanwhile, a statistical difference was found between shockwave therapy and fumigation in functional improvement ($P < 0.05$) but not in pain reduction ($P = 0.26$). Additionally, there was no statistically significant difference between shockwave therapy and manipulation in both pain reduction ($P = 0.21$) and functional improvement ($P = 0.45$). No serious adverse reaction occurred in all of studies.

Conclusions. Extracorporeal shockwave therapy could be recommended in the treatment of osteoarthritis as a noninvasive therapy with safety and effectiveness, but the grade of recommendations needs to be discussed in a further study.

1. Background

Osteoarthritis (OA) is the most common musculoskeletal disease, ranking as the 11th highest contributor to global disability and 38th highest in the disability-adjusted life years (DALYs) in the Global Burden of Disease 2010 study [1, 2]. About 18% of women and 10% of men over 60 years of age suffered from OA and had higher mortality rates than their peers [3, 4]. In recent studies, the pathological processes of OA involve several local and systemic factors such as cytokines, chemokines, inflammatory mediators, matrix degradation, cell-derived, and/or matrix-derived products, which may cause damages to the synovium, cartilage, subchondral bone, periarticular muscles, ligaments, and other joint structures and finally lead to pain, stiffness, and disability [5, 6]. At present, the medical management of OA includes surgical therapies and nonsurgical therapies such as intra-articular injection, medication, and physical therapy. However, it was still difficult to reverse the destruction of joint structures [5]. Therefore, it is of great clinic significance to find an ideal method to relieve pain, improve function, and delay the disease progression.

As a new technique, extracorporeal shockwave therapy (ESWT) uses a single-impulse transient acoustic wave induced by pneumatic, electrohydraulic, electromagnetic, or piezoelectric generators which focus on the area needed to
be treated [7]. ESWT has shown an effect on articular cartilage and subchondral bone development, neovascularization, tissue regeneration, and inflammatory response in some animal experiments [8–10]. ESWT also succeeds in the treatment of several musculoskeletal diseases, including tennis elbow syndrome, plantar fasciitis, tendon disease, and fracture nonunions, in some clinical studies [11–14]. More and more attention has been paid to the application of ESWT on OA because of its noninvasive nature, low rate of complications, and low cost compared with other surgical or conservative treatments in recent studies [15, 16]. Despite some systematic reviews focusing on the effect of ESWT on knee OA [17–19], there was no systematic review to confirm the value of ESWT in the treatment of all types of OA (including knee OA and carpalometacarpal joint OA) and compare ESWT with other traditional therapies (especially traditional Chinese medicine). Thus, this meta-analysis was performed, and the latest randomized controlled trials were included, which would contribute to the treatment of OA.

2. Method

2.1. Search Strategy. The protocol was registered in the PROSPERO database (CRD42019120534), and all searched results were evaluated according to the PRISMA statement. PubMed, MEDLINE, the Cochrane Central Register of Controlled Trials, Web of Science (WOS), Chinese National Knowledge Infrastructure (CNKI), WANFANG database, and VIP database were searched up to December 10, 2019, to identify the potential studies exploring the effect of ESWT for the treatment of OA. The searching strategy used was as follows: (((extracorporeal shock wave therapy [Title/Abstract]) OR ESWT[Title/Abstract]) AND ((osteoarthritis[Title/Abstract]) OR OA[Title/Abstract])) Filters: Publication date to 2019/12/10. The Publication language was limited to English and Chinese.

2.2. Study Selection. The inclusion criteria were the following: (1) randomized controlled trials (RCT) comparing the effect of ESWT and other treatments (including placebo) for all types of OA; (2) full text available and the outcome of experiments including mean (M), standard deviation (SD), and number (N); (3) patients aged 45 years or more and diagnosed with OA according to any clinical criteria; and (4) ESWT that had never been performed to the enrolled patients before.

The exclusion criteria were the following: (1) meta-analyses, reviews, letters, editorials, expert opinions, case reports, and nonrandomized control trials; (2) animal experiments; (3) patients with coagulopathy, pregnancy, cancer, history of fractures, cardiac pacemaker use, and neurologic conditions; and (4) including only the latest information if data were duplicated or overlapped.

2.3. Screening and Data Collection. Two researchers independently assessed the eligibility of the studies, and the disagreements were resolved by a third verdict. Titles and abstracts were screened to identify the related studies, and then full texts were assessed carefully. Moreover, the references cited in the selected articles were explored to identify the potentially relevant studies. The scores of visual analogue scale (VAS) were extracted as primary outcome. Secondary outcomes included the scores of the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), which represented the functional change. If the scores were recorded in different follow-up times, we selected the time point at 3 months or available data to be nearest to 3 months to predict the efficacy.

2.4. Quality Assessment. The quality of included studies was assessed by the Cochrane Collaboration’s tool for assessing the risk of bias which was recommended for systematic reviews of interventions in Cochrane Handbook version 5.1.0 [20]. We evaluated 7 domains of bias including selection bias, performance bias, detection bias, attribution bias, reporting bias, and other sources of bias. The judgements were expressed as “high risk,” “low risk,” or “unclear risk,” and the quality assessment figure was generated by RevMan version 5.3.

2.5. Statistical Analyses. Meta-analysis Review Manager software (RevMan version 5.3; The Cochrane Collaboration 2014) and STATA (version 12.0; Stata Corporation) were used for data analysis. The analysis was performed in two respects including pain reduction and functional improvement. The heterogeneity was evaluated by Higgins I2 statistic, $I^2 > 50\%$ was defined as significant heterogeneity among studies, and the random effects model was applied for the pooled effect estimates. Otherwise, the fixed effects model was used. At the same time, subgroup analysis was used for exploring sources of heterogeneity and reassessing the results. Sensitivity analyses were performed by removing an individual study from the meta-analysis each time. If more than 10 studies were included in each meta-analysis, the possibility of publication bias would be evaluated by Egger’s test and $P < 0.05$ was considered statistically significant; then the fill method and nonparametric trim were applied to correct the effect size. The results were expressed as the standard mean difference (SMD) and 95% confidence interval (95% CI) for continuous outcome data.

3. Result

3.1. Search Results. As shown in Figure 1, the initial search yielded 549 articles and 173 records were screened after removing duplicates. The title and abstract of potentially relevant studies were read carefully, and 118 records were excluded. Then 55 full-text articles were assessed, and 23 articles were excluded because they did not meet the inclusion criteria. Finally, 32 RCTs were included in this meta-analysis [21–52]. Characteristics of these studies are shown in Table 1. All of the articles were published between 2013 and 2019 in English or Chinese. The sample size ranged from 18 to 160. All experimental groups received ESWT, while control groups received different treatments including placebo [22, 23, 25, 26, 28, 30, 34, 48, 49, 51, 52], medication [31, 32, 43, 44, 50], intra-articular injections [21, 26, 27, 29, 35, 36, 39, 40], traditional Chinese medicine [38, 41, 42, 45,
46], ultrasound [22, 24, 47], surgery [33], and kinesiotherapy (KIN) [37].

3.2. ESWT vs. Placebo. A statistically significant difference between ESWT group and placebo group was found in pain reduction (SMD = -1.44, 95% CI: -1.77 to -1.10, P < 0.00001) and functional improvement (SMD = -1.84, 95% CI: -2.47 to -1.20, P < 0.00001). As shown in Figure 2, high heterogeneity was observed in the analysis of pain reduction (I² = 72%). After removing a study [25] from the meta-analysis, the heterogeneity decreased to 0%. The same phenomenon occurred in the analysis of functional improvement; the heterogeneity decreased from 89% to 30% after removing two studies [25, 26] from the meta-analysis, which suggested these two studies might be the sources of heterogeneity. The pooled effect did not change after removing these studies (P < 0.00001), which indicated the result was robust.

3.3. ESWT vs. Intra-Articular Injections. As shown in Figure 3, there was a statistical difference between the ESWT group and hyaluronic acid intra-articular injection (HA) group in pain reduction (SMD = -0.39, 95% CI: -0.77 to -0.01, P = 0.04) and functional improvements (SMD = -0.64, 95% CI: -1.24 to -0.04, P = 0.04). The heterogeneity decreased after subgroup analysis, which suggested that the language and dose of HA might be potential sources of heterogeneity.

A statistically significant difference between the ESWT group and platelet-rich plasma (PRP) intra-articular injection group was observed in pain reduction (SMD = -0.40, 95% CI: -0.76 to -0.03, P = 0.03). However, there was no statistically significant difference in functional improvement (SMD = -0.02, 95% CI: -0.38 to 0.33, P = 0.89).

There was a statistically significant difference between the ESWT group and corticosteroid intra-articular injection group in pain reduction (SMD = -1.68, 95% CI: -2.41 to -0.95, P < 0.00001) and functional improvements (SMD = -7.87, 95% CI: -9.78 to -5.95, P < 0.00001).

3.4. ESWT vs. Medication. There was a statistically significant difference between the ESWT group and medication group in pain reduction (SMD = -1.67, 95% CI: -2.38 to -0.97, P < 0.00001) and functional improvement (SMD = -1.09, 95% CI: -1.33 to -0.85, P < 0.00001). High heterogeneity was found in pain reduction (I² = 88%). In functional improvement, no heterogeneity was observed (I² = 0%) (Figure 4).

3.5. ESWT vs. Ultrasound. As shown in Figure 5, a statistically significant difference was observed between the ESWT group and ultrasound group in pain reduction (SMD = -0.65, 95% CI: -0.92 to -0.37, P < 0.00001) and
| Author       | Publication year | Country | Language | Sample size | Control group | Experimental group | Outcome measures | Follow-up time | Type of OA | Type of ESWT |
|--------------|------------------|---------|----------|-------------|---------------|--------------------|-----------------|----------------|------------|--------------|
| Ediz         | 2018             | Turkey  | English  | 73          | Placebo       | ESWT 2 times/week  | VAS, WOMAC      | 6 M            | Knee       | Focused ESWT |
| Ioppolo      | 2018             | Rome    | English  | 58          | HA (3 injections of 0.5 cm³ HA) 1 time/week Total of 3 weeks | ESWT 1 time/week | VAS              | 3 M            | Carpometacarpal joint | Focused ESWT |
| Lee          | 2017             | Korea   | English  | 61          | HA (1 injection of 2 mL of HA) 1 time/week Total of 3 weeks | ESWT 1 time/week | VAS, WOMAC      | 3 M            | Knee       | Focused ESWT |
| Lizis        | 2017             | Poland  | English  | 40          | KIN 1 time/week Total of 3 weeks | ESWT 1 time/week | WOMAC           | 5 W            | Knee       | Unmentioned  |
| Zhao         | 2013             | China   | English  | 70          | Placebo       | ESWT 1 time/week  | VAS, WOMAC      | 3 M            | Knee       | Radial ESWT  |
| Liu Y        | 2016             | China   | Chinese  | 86          | Placebo       | ESWT 1 time/week  | VAS, WOMAC      | 3 M            | Knee       | Radial ESWT  |
| Liu MY       | 2017             | China   | Chinese  | 158         | Medication (celecoxib) oral 200 mg qd 4 weeks | ESWT 1 time/week | VAS, WOMAC      | 3 M            | Knee       | Unmentioned  |
| Zhang        | 2017             | China   | Chinese  | 106         | Ultrasound 5 times/week Total of 4 weeks | ESWT 1 time/week | VAS              | 1 M            | Knee       | Radial ESWT  |
| Zheng        | 2016             | China   | Chinese  | 48          | Medication (celecoxib) oral 200 mg qd 4 weeks | ESWT 1 time/week | VAS, WOMAC      | 1 M            | Knee       | Radial ESWT  |
| Liu WT       | 2017             | China   | Chinese  | 58          | Acupotomy surgery | ESWT 1 time/5 days Total of 6 times | WOMAC           | 5 W            | Knee       | Unmentioned  |
| ZhaoAQ       | 2016             | China   | Chinese  | 60          | Placebo       | ESWT 1 time/week  | VAS, WOMAC      | 2 M            | Knee       | Unmentioned  |
| Wu           | 2014             | China   | Chinese  | 53          | Medication (toricoxi) oral 60 mg qd 4 weeks | ESWT 1 time/week | VAS              | 6 W            | Knee       | Radial ESWT  |
| Chen         | 2014             | China   | English  | 120         | Placebo       | ESWT 1 time/week  | VAS              | 2 M            | Knee       | Focused ESWT |
| Author  | Publication year | Country  | Language | Sample size | Control group                      | Experimental group                                                                 | Outcome measures | Follow-up time | Type of OA | Type of ESWT |
|---------|------------------|----------|----------|-------------|------------------------------------|--------------------------------------------------------------------------------------|------------------|----------------|------------|--------------|
| Lee JH  | 2017             | Korea    | English  | 20          | Placebo                            | ESWT 3 times/week Total of 4 weeks                                                   | VAS WOMAC       | 1 M            | Knee       | Focused ESWT |
| Zhong   | 2019             | China    | English  | 63          | Placebo                            | ESWT 1 time/week Total of 4 weeks                                                   | VAS WOMAC       | 3 M            | Knee       | Radial ESWT  |
| Wang    | 2016             | China    | Chinese  | 78          | Massage manipulation 1 time/2 days 10 weeks | ESWT 1 time/5 days Total of 5 weeks                                                 | WOMAC           | 3 M            | Knee       | Radial ESWT  |
| Zhong   | 2018             | China    | Chinese  | 63          | Placebo                            | ESWT 1 time/week Total of 4 weeks                                                   | VAS WOMAC       | 5 W            | Knee       | Radial ESWT  |
| Xie     | 2019             | China    | Chinese  | 60          | Fumigation bid 3 weeks             | ESWT 1 time/week Total of 4 weeks                                                   | VAS WOMAC       | 3 M            | Knee       | Radial ESWT  |
| Su      | 2018             | China    | Chinese  | 160         | HA (1 injection of 2 mL of HA) 1 time/week Total of 5 weeks | ESWT 1 time/week Total of 5 weeks                                                 | VAS WOMAC       | 5 W            | Knee       | Radial ESWT  |
| Su      | 2019             | China    | Chinese  | 120         | PRP (1 injection of 4 mL of PRP) 1 time/week Total of 5 weeks | ESWT 1 time/week Total of 5 weeks                                                 | VAS WOMAC       | 5 W            | Knee       | Radial ESWT  |
| Qi      | 2015             | China    | Chinese  | 60          | Acupoint moxibustion qd 4 weeks    | ESWT 1 time/week Total of 4 weeks                                                   | WOMAC           | 6 M            | Knee       | Focused ESWT |
| Yang    | 2017             | China    | Chinese  | 86          | Fumigation qd 16 days              | ESWT 1 time/5 days Total of 4 weeks                                                 | WOMAC           | After treatment | Knee       | Radial ESWT  |
| Liu ZC  | 2019             | China    | Chinese  | 77          | HA (1 injection of 2.5 mL of HA) 1 time/week Total of 5 weeks | ESWT 1 time/week Total of 5 weeks                                                 | VAS WOMAC       | 5 W            | Knee       | Radial ESWT  |
| Wu TY   | 2018             | China    | Chinese  | 100         | Medication (celecoxib) oral 200 mg qd 4 weeks | ESWT 1 time/week Total of 4 weeks                                                 | VAS WOMAC       | After treatment | Knee       | Radial ESWT  |
| Cai     | 2018             | China    | Chinese  | 90          | HA (1 injection of 2.5 mL of HA) 1 time/week Total of 5 weeks | ESWT 1 time/week Total of 4 weeks                                                 | VAS WOMAC       | 3 M            | Knee       | Radial ESWT  |
| Wei     | 2018             | China    | Chinese  | 40          | Massage manipulation 3 times/week Total of 4 weeks | ESWT 1 time/week Total of 4 weeks                                                 | VAS WOMAC       | 6 W            | Knee       | Radial ESWT  |
| Author | Publication year | Country | Language | Sample size | Control group | Experimental group | Outcome measures | Follow-up time | Type of OA | Type of ESWT |
|--------|------------------|---------|----------|-------------|---------------|-------------------|-----------------|----------------|------------|-------------|
| Cho    | 2016             | Korea   | English  | 18          | Placebo       | ESWT 1 time/week  | VAS             | 1 W            | Knee       | Focused ESWT |
| Liu YX | 2018             | China   | Chinese  | 72          | HA (1 injection of 20 mg of HA) | ESWT 2 times/week | VAS WOMAC      | 2 M            | Knee       | Unmentioned |
| Liu BZ | 2019             | China   | Chinese  | 63          | Placebo       | ESWT 1 time/week  | VAS WOMAC      | 3 M            | Knee       | Radial ESWT |
| Elerian | 2016             | Egypt   | English  | 60          | Placebo corticosteroid injection 1 time/month | ESWT 1 time/week  | VAS WOMAC      | 2 M            | Knee       | Radial ESWT |
| Liu WF | 2019             | China   | Chinese  | 66          | Medication (celecoxib) oral 200 mg qd 4 weeks | ESWT 1 time/week  | VAS             | After treatment | Knee       | Radial ESWT |
| Dou    | 2016             | China   | Chinese  | 121         | Ultrasound    | ESWT              | WOMAC           | 1 M            | Knee       | Focused ESWT |

Abbreviations: RCT: randomized controlled trial; ESWT: extracorporeal shockwave therapy; HA: hyaluronic acid intra-articular injections; PRP: platelet-rich plasma; KIN: kinesiotherapy; VAS: visual analogue scale; WOMAC: Western Ontario and McMaster Universities Osteoarthritis Index; W: weeks; M: months; qd: once a day; bid: twice a day; OA: osteoarthritis.
95% CI: -1.74 to -0.81, reduction (SMD = 0.57, 95% CI: -0.23 to 1.03, P = 0.54). There was no statistically significant difference in functional improvement (SMD = -1.17, 95% CI: -2.90 to -1.32, P = 0.00001). No heterogeneity was observed in this meta-analysis (I^2 = 0%).

3.6. ESWT vs. Surgery. There was no statistically significant difference between the ESWT group and acupotomy surgery group in functional improvement (SMD = 0.31, 95% CI: -0.21 to 0.83, P = 0.24). (Figure 6)

3.7. ESWT vs. KIN. In Figure 7, a statistically significant difference was observed between the ESWT group and kinesiotherapy (KIN) group in functional improvement (SMD = -2.11, 95% CI: -2.90 to -1.32, P = 0.00001).

3.8. ESWT vs. Traditional Chinese Medicine. As shown in Figure 8, there was no statistically significant difference between the ESWT group and manipulation group in pain reduction (SMD = 0.40, 95% CI: -0.23 to 1.03, P = 0.21) and functional improvement (SMD = 0.47, 95% CI: -1.71 to 0.76, P = 0.45). A statistically significant difference was found in comparison between the ESWT group and fumigation group in functional improvement (SMD = -1.28, 95% CI: -1.74 to -0.81, P < 0.00001) but not in pain reduction (SMD = -0.29, 95% CI: -0.80 to 0.22, P = 0.26).

There was a statistically significant difference between the ESWT group and acupoint moxibustion group in functional improvement (SMD = -0.60, 95% CI: -1.12 to -0.09, P = 0.02).

3.9. Adverse Event. Only temporary pain, minor bruising, or transient soft tissue swelling was observed in nine studies [25, 30, 34, 42, 44, 47, 50–52]. No adverse events were observed during the treatment in other six studies [27, 29, 36–38, 46], and the remaining studies did not mention it.

3.10. Sensitivity Analysis. In meta-analysis comparing ESWT with placebo, a single study was excluded each time to evaluate the impact of the individual data on the whole result. The results showed that the pooled effect was robust and no significant deviation from the overall results was detected in our study (Figure 9).

3.11. Quality Assessment and Publication Bias. In quality assessment (Figure 10), 19 studies were considered to be high risk in blinding of participants and personnel because the therapeutic properties make it hard to apply blinding. 155 of 224 domains (69.2%) were determined at low risk, and 50 of 224 domains (22.3%) were determined at unclear risk.

**Figure 2**: Forest plot comparing the ESWT group with the placebo group.
4. Discussion

This meta-analysis included 32 studies involving 2408 patients to explore the efficacy and safety of ESWT for the
treatment of OA. In this study, the ESWT group showed a statistically significant difference compared with the placebo, corticosteroid, HA, medication, and ultrasound group in both pain reduction and functional improvement, presenting that ESWT might be a successful alternative treatment when above treatments are unavailable. In functional improvement, ESWT showed statistical improvement compared with kinesiotherapy and moxibustion but no statistical difference.
### Comparison of functional improvement

| Study or subgroup | ESWT Mean | SD | Total Mean | SD | Total | Weight | Std. mean difference | IV, random, 95% CI | Std. mean difference | IV, random, 95% CI |
|------------------|-----------|----|------------|----|-------|--------|----------------------|----------------------|----------------------|----------------------|
| Lizis 2017       | 33        | 4  | 20         | 48 | 20    | 100.0% | -2.11                | [-2.90, -1.32]       |                      |                      |
| Total (95% CI)   | 20        | 20 | 100.0%     | -2.11 | [-2.90, -1.32]       |                      |                      |

Heterogeneity: not applicable
Test for overall effect: $Z = 5.25$ ($P < 0.00001$)

**Figure 7:** Forest plot comparing the ESWT group with the KIN group.

### Comparison of pain reduction (manipulation)

| Study or subgroup | Manipulation Mean | SD | Total Mean | SD | Total | Weight | Std. mean difference | IV, random, 95% CI | Std. mean difference | IV, random, 95% CI |
|-------------------|------------------|----|------------|----|-------|--------|----------------------|----------------------|----------------------|----------------------|
| Wei 2018          | 3.8              | 1.06 | 20         | 3.35 | 1.14 | 20     | 100.0%              | 0.40 [-0.23, 1.03]    | 0.40 [-0.23, 1.03]    |                      |
| Total (95% CI)    | 20                | 20  | 100.0%     | 0.40 | [-0.23, 1.03]    |                      |                      |

Heterogeneity: not applicable
Test for overall effect: $Z = 1.25$ ($P = 0.21$)

**Figure 8:** Forest plot comparing the ESWT group with the traditional Chinese medicine group.
compared with acupotomy surgery. A significant difference between ESWT and PRP was observed in pain reduction but not in functional improvement. Meanwhile, a statistical difference was found between ESWT and fumigation in functional improvement but not in pain reduction. Additionally, there was no statistically significant difference between ESWT and manipulation in both pain reduction and functional improvement. No serious adverse reaction occurred in all of studies.

Osteoarthritis (OA) is the most common cause leading to musculoskeletal pain [53]. It is considered that the pathological features of OA include articular cartilage destruction, subchondral bone change, osteophyte formation remodeling, ligamentous laxity, periarticular muscle weakness, and
synovial inflammation, which could result in chronic pain, physical limitation, and joint stiffness [54, 55].

Traditional treatments of OA included nonsurgical therapies and surgical therapies. In the 2014 Osteoarthritis Research Society International guidelines for the management of knee OA, nonsurgical therapies included intra-articular corticosteroids, biomechanical interventions, exercise, education and self-management, weight management, and strength training [56]. Traditional surgical options included joint sparing procedures such as arthroscopic surgery or joint replacing procedures [57]. For treatment, nonsurgical therapy might have limited benefit and could be associated with serious adverse events such as bleeding or gastrointestinal ulcers caused by nonsteroidal anti-inflammatory drugs (NSAIDs) and infection caused by intra-articular injection [58]. As for surgery, it might be inappropriate for aged patients with limiting comorbidities. In such conditions, an effective and safe treatment was needed for patients with OA.

ESWT has been increasingly used in clinical practice over the past few years and shows significant efficacy in some clinical studies [16, 59–61]. It is suggested that ESWT can generate radial or focused pressure waves which bring energy and propagate through tissue [62]. This physical force could stimulate biological effects in a treated area, and the biochemical mechanism of ESWT in OA might be associated with neovascularization, osteogenesis, and chondrogenesis [63–65]. In recent studies, ESWT might lead to upregulation of angiogenic growth factors including endothelial nitric oxide synthase (eNOS) and vessel endothelial growth factor (VEGF), which benefit to neovascularization [66]. ESWT was also found connected with osteogenic transcription factors including VEGF-A and hypoxia inducible factor-1α (HIF-1α), affecting growth of osteoblasts [67]. Meanwhile, ESWT might elevate levels of nitric oxide (NO), bone morphogenetic protein-2 (BMP-2), protein kinase B (PKB), and transforming growth factor-beta 1 (TGF-β1), which facilitate differentiation and proliferation of osteoblasts [68–71]. Also, it was suggested that ESWT could enhance the expression of Pdia-3, a key point of 1α,25-dihydroxyvitamin D3 (1α,25(OH)2D3) signaling pathway [72]. This signaling pathway is essential in gene transcription and calcium homeostasis, which was considered beneficial for osteogenesis [73]. Besides, ESWT was revealed to have a dose-dependent effect on the metabolism of mesenchymal stem cells (MSCs), which potentially improve bone regeneration and chondrogenesis [74]. However, the exact mechanism of ESWT is still unknown, and further studies are required for better clinical utilization.

This study also had some limitations. First, we only searched studies in English and Chinese; thus, some potential relative studies in other languages might have been missed. Second, unreported negative results and gray literature could result in publication bias. Third, very few studies compared ESWT with surgery, PRP, and corticosteroid intra-articular injections, traditional Chinese medicine, or kinesiotherapy; thus, the subgroup analysis and sensibility analysis could not be performed, and the outcome might be misleading. Besides, in this meta-analysis, focused ESWT was performed in 8 studies in the experiment group and radial ESWT was
administered in 19 studies, while the type of ESWT was unmentioned in the other 5 studies. As a result, it was difficult to perform subgroup analysis according to the different type of ESWT and analyze whether there was a difference between the focused ESWT and radial ESWT in the treatment of OA. Further studies could be carried out to improve this issue.

5. Conclusion

In conclusion, ESWT showed a significant effect in the treatment of OA in pain reduction or/and functional improvement compared with placebo, corticosteroid, HA, medication, ultrasound, moxibustion, fumigation, PRP, and kinesiotherapy. However, ESWT failed to show a statistically significant difference compared with manipulation and surgery. As a result, ESWT could be recommended in the treatment of OA as a noninvasive therapy with safety and effectiveness but the grade of recommendations needs to be discussed in a further study.

Disclosure

The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. An earlier version of this work has been presented in 22th ISMST International Congress.

Conflicts of Interest

The authors have no conflicts of interest to declare.

Authors’ Contributions

Ye L designed the study with contributions from Chen L. Yang PL and Yang BX screened and collected the data. Liu H carried out the quality assessment. Chen L analyzed the data and wrote the paper with the help from Ye L and Yang PL.

Acknowledgments

This work was supported by grant 2019HXFH069 from 1.3.5 Project for Disciplines of Excellence–Clinical Research Incubation Project, West China Hospital, Sichuan University. The authors thank the authors of the eligible studies for providing the data.

References

[1] S. Glyn-Jones, A. J. Palmer, R. Agricola et al., “Osteoarthritis,” Lancet, vol. 386, no. 9991, pp. 376–387, 2015.
[2] M. Cross, E. Smith, D. Hoy et al., “The global burden of hip and knee osteoarthritis: estimates from the Global Burden of Disease 2010 study,” Annals of the Rheumatic Diseases, vol. 73, no. 7, pp. 1323–1330, 2014.
[3] D. Pereira, E. Ramos, and J. Branco, "Osteoarthritis," Acta Médica Portuguesa, vol. 28, no. 1, pp. 99–106, 2015.
[4] A. M. Briggs, M. J. Cross, D. G. Hoy et al., “Musculoskeletal health conditions represent a global threat to healthy aging: a report for the 2015 World Health Organization world report on ageing and health,” Gerontologist, vol. 56, Supplement 2, pp. S243–S255, 2016.
[5] J. N. Katz, “Tanezumab for painful osteoarthritis,” JAMA, vol. 322, no. 1, pp. 30–32, 2019.
[6] J. Martel-Pelletier, A. J. Barr, F. M. Cicuttini et al., "Osteoarthritis," Nature Reviews Disease Primers, vol. 2, no. 1, article 16072, 2016.
[7] Q. Ji, P. Wang, and C. He, “Extracorporeal shockwave therapy as a novel and potential treatment for degenerative cartilage and bone disease: osteoarthritis. A qualitative analysis of the literature,” Progress in Biophysics and Molecular Biology, vol. 121, no. 3, pp. 255–265, 2016.
[8] C. J. Wang, “Extracorporeal shockwave therapy in musculoskeletal disorders,” Journal of Orthopaedic Surgery and Research, vol. 7, no. 1, p. 11, 2012.
[9] J. H. Cheng, C. J. Wang, S. H. Su, C. Y. Huang, and S. L. Hsu, “Next-generation sequencing identifies articular cartilage and subchondral bone miRNAs after ESWT on early osteoarthritis knee,” Oncotarget, vol. 7, no. 51, pp. 84398–84407, 2016.
[10] N. Ochiai, S. Ohtori, T. Sasho et al., “Extracorporeal shock wave therapy improves motor dysfunction and pain originating from knee osteoarthritis in rats,” Osteoarthritis and Cartilage, vol. 15, no. 9, pp. 1093–1096, 2007.
[11] A. Kubot, A. Grzegorzewski, M. Synder, W. Szymczak, and P. Kozlowski, “Radial extracorporeal shockwave therapy and ultrasound therapy in the treatment of tennis elbow syndrome,” Ortopedia Traumatologia Rehabilitacja, vol. 19, no. 5, pp. 415–426, 2017.
[12] W. Schaden, R. Mittermayr, N. Haffner, D. Smolen, L. Gerdesmeyer, and C. J. Wang, “Extracorporeal shockwave therapy (ESWT) - First choice treatment of fracture nonunions?,” International Journal of Surgery, vol. 24, no. Part B, pp. 179–183, 2015.
[13] J. Lou, S. Wang, S. Liu, and G. Xing, “Effectiveness of extracorporeal shock wave therapy without local anesthesia in patients with calcific plantar fasciitis: a meta-analysis of randomized controlled trials,” American Journal of Physical Medicine & Rehabilitation, vol. 96, no. 8, pp. 529–534, 2017.
[14] C. Carulli, F. Tonelli, M. Innocenti, B. Gambardella, F. Muncibì, and M. Innocenti, “Effectiveness of extracorporeal shockwave therapy in three major tendon diseases,” Journal of Orthopaedics and Traumatology, vol. 17, no. 1, pp. 15–20, 2016.
[15] W. Y. Chou, J. H. Cheng, C. J. Wang, S. L. Hsu, J. H. Chen, and C. Y. Huang, “Shockwave targeting on subchondral bone is more suitable than articular cartilage for knee osteoarthritis,” International Journal of Medical Sciences, vol. 16, no. 1, pp. 156–166, 2019.
[16] S. Kang, F. Gao, J. Han et al., “Extracorporeal shock wave treatment can normalize painful bone marrow edema in knee osteoarthritis: a comparative historical cohort study,” Medicine, vol. 97, no. 5, article e9796, 2018.
[17] Y. C. Wang, H. T. Huang, P. J. Huang, Z. M. Liu, and C. L. Shih, “Efficacy and safety of extracorporeal shockwave therapy for treatment of knee osteoarthritis: a systematic review and meta-analysis,” Pain Medicine, 2019.
[18] T. Li, J. Ma, T. Zhao, F. Gao, and W. Sun, “Application and efficacy of extracorporeal shockwave treatment for knee
osteoarthritis: a systematic review and meta-analysis,” *Experimental and Therapeutic Medicine*, vol. 18, no. 4, pp. 2843–2850, 2019.

[19] C. D. Liao, J. Y. Tsauto, T. H. Liou, H. C. Chen, and S. W. Huang, “Clinical efficacy of extracorporeal shockwave therapy for knee osteoarthritis: a systematic review and meta-regression of randomized controlled trials,” *Clinical Rehabilitation*, vol. 33, no. 9, pp. 1419–1430, 2019.

[20] J. J. Deeks, J. Higgins, D. G. Altman, and S. Green, *Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0* [updated March 2011], The Cochrane Collaboration, 2011, http://www-handbook.cochrane.org/.

[21] J. X. Cai, *The effects of extracorporeal shock wave therapy for knee osteoarthritis*, Fujian Medical University, 2018.

[22] T. W. Chen, C. W. Lin, C. L. Lee et al., “The efficacy of shock wave therapy in patients with knee osteoarthritis and popliteal cystamella,” *The Kaohsiung Journal of Medical Sciences*, vol. 30, no. 7, pp. 362–370, 2014.

[23] S. J. Cho, J. R. Yang, H. S. Yang, and H. E. Yang, “Effects of extracorporeal shockwave therapy in chronic stroke patients with knee osteoarthritis: a pilot study,” *Annals of Rehabilitation Medicine*, vol. 40, no. 5, pp. 862–870, 2016.

[24] Y. X. Dou, J. Yuan, and J. Y. Zhao, “Short-term effect analysis of extracorporeal shock wave on knee osteoarthritis,” *Chinese Journal of Rehabilitation Medicine*, vol. 31, no. 8, pp. 917–919, 2016.

[25] L. Ediz and M. Orgokce, “Effectiveness of extracorporeal shock wave therapy to treat primary medial knee osteoarthritis with and without bone marrow edema in elderly patients,” *Turkish Journal of Geriatrics-Turk Gierrati Dergisi*, vol. 21, no. 3, pp. 394–401, 2018.

[26] A. E. Elerian, T. M. A. Ewidea, and N. Ali, “Effect of shock wave Therapy versus corticosteroid injection in management of knee osteoarthritis,” *International Journal of Physiotherapy*, vol. 3, no. 2, pp. 246–251, 2016.

[27] F. Ioppolo, F. Saracino, R. S. Rizzo et al., “Comparison between extracorporeal shock wave therapy and intra-articular hyaluronic acid injections in the treatment of first carpometacarpal joint osteoarthritis,” *Annals of Rehabilitation Medicine*, vol. 42, no. 1, pp. 92–100, 2018.

[28] J. H. Lee, S. Lee, S. Choi, Y. H. Choi, and K. Lee, “The effects of extracorporeal shock wave therapy on the pain and function of patients with degenerative knee arthritis,” *Journal of Physical Therapy Science*, vol. 29, no. 3, pp. 536–538, 2017.

[29] K.-K. Lee, B.-Y. Lee, W.-Y. Shin, M. J. An, K. I. Jung, and S. R. Yoon, “Effect of extracorporeal shockwave therapy versus intra-articular injections of hyaluronic acid for the treatment of knee osteoarthritis,” *Annals of Rehabilitation Medicine-Arm*, vol. 41, no. 5, pp. 828–835, 2017.

[30] B. Z. Liu, Z. Y. Zhong, G. H. Liu et al., “The effects of extracorporeal shock wave therapy on the lower limb function and articular cartilage of patients with knee osteoarthritis,” *Chinese Journal of Physical Medicine and Rehabilitation*, vol. 41, no. 7, pp. 494–498, 2019.

[31] M. Y. Liu, H. Li, Y. Q. Zhang et al., “Efficacy of extracorporeal shock wave therapy in elderly patients with knee osteoarthritis and its influence on inflammatory factors,” *Hainan Medical Journal (Hai Nan Yi Xue)*, vol. 28, no. 24, pp. 4015–4017, 2017.

[32] W. F. Liu, “Effects of extracorporeal shock wave therapy on early to mid-term knee osteoarthritis,” *China Medical Device Information*, vol. 25, no. 8, pp. 61–62, 2019.

[33] W. T. Liu, K. L. Xue, M. Tian, and F. Zhang, “Comparative study of pneumatic lithotripsy extracorporeal shock wave and acupotomy in the treatment of knee osteoarthritis,” *The Journal of Cervicodynia and Lumbodynia*, vol. 38, no. 1, pp. 64–67, 2017.

[34] Y. Liu, *Efficacy of shockwave therapy in postmenopausal women with early metaphase knee osteoarthritis*, Hebei Medical University, 2016.

[35] Y. X. Liu, H. L. Zhou, L. L. Xu, and T. T. Li, “Effect of extracorporeal shockwave combined with rehabilitation measures on Coll 2-1 and COMP level in patients with early and middle stage knee osteoarthritis,” *Orthopaedics*, vol. 9, no. 4, pp. 302–305, 2018.

[36] Z. C. Liu, J. Song, and Q. L. Zhang, “Extracorporeal shock wave therapy versus intra-articular injection of sodium hyaluronate for knee osteoarthritis,” *Chinese Journal of Tissue Engineering Research*, vol. 23, no. 15, pp. 2297–2302, 2019.

[37] P. Lizis, W. Kobza, and G. Manko, “Extracorporeal shockwave therapy vs. kinesiotherapy for osteoarthritis of the knee: a pilot randomized controlled trial,” *Journal of back and musculeskelletal rehabilitation*, vol. 30, no. 5, pp. 1121–1128, 2017.

[38] S. Qi, X. H. Li, X. Q. Wu, and X. B. Lu, “The effect of extracorporeal shock wave combined with thermal moxibustion on knee osteoarthritis,” *Chinese Journal of Physical Medicine and Rehabilitation*, vol. 37, no. 2, pp. 120–122, 2015.

[39] W. Z. Su, Y. Lin, G. Wang et al., “Prospective clinical study on extracorporeal shock wave therapy combined with plateletrich plasma injection for knee osteoarthritis,” *Chinese Journal of Reparative and Reconstructive Surgery*, vol. 33, no. 12, pp. 1–5, 2019.

[40] W. Z. Su, Y. J. Lin, G. W. Wang, and Z. Geng, “Therapeutic efficacy of extracorporeal shock wave therapy combined with sodium hyaluronate injection on knee osteoarthritis,” *Chinese Journal of Anatomy and Clinics*, vol. 23, no. 5, pp. 418–421, 2018.

[41] L. L. Wang, Y. Dong, S. Liang et al., “et alClinical application of radial shock wave therapy in knee osteoarthritis,” *The Journal of Cervicodynia And Lumbodynia*, vol. 37, no. 4, pp. 354–355, 2016.

[42] Y. Wei, *Clinical efficacy of extracorporeal shock wave combined with manipulation in the treatment of knee osteoarthritis*, Guangxi University of Chinese Medicine, 2018.

[43] T. Y. Wu, X. Zhao, and Y. Guo, “Evaluation of the effect of extracorporeal shock wave on early and middle stage osteoarthritis,” *Psychological Doctor*, vol. 24, no. 27, pp. 121–122, 2018.

[44] W. Wu, L. Ye, B. J. Zheng et al., “Efficacy and safety of extracorporeal shock wave therapy for knee osteoarthritis,” *Shanghai Medical Journal*, vol. 37, no. 8, pp. 669–672, 2014.

[45] B. Z. Xie, D. D. Li, N. Yin, and Z. W. Wang, “The clinical study of extracorporeal shock wave therapy plus TCM medicine fumigation with Pingle Xitongning plus shock wave,” *Clinical Journal of Orthopaedics*, vol. 11, no. 4, pp. 109–111, 2019.

[46] Z. W. Yang Qinxian, C. Cuiping, C. Zhe, and T. Yongsheng, “A clinical study on treating knee osteoarthritis by extracorporeal shock wave plus TCM medicine fumigation,” *Clinical Journal of Chinese Medicine*, vol. 9, no. 35, pp. 81–83, 2017.

[47] T. Zhang, W. B. Liu, H. Li, and L. Xiao, “The clinical study of radial shock wave therapy in the treatment of knee osteoarthritis,” *Medical Innovation of China*, vol. 14, no. 30, pp. 36–40, 2017.
[48] A. Q. Zhao, W. L. Xie, and Y. Wang, "Effect of extracorporeal shock wave on the level of chemein in serum and synovia in patients with knee osteoarthritis," Medical Journal of Southeast China, vol. 18, no. 5, pp. 498–500, 2016.

[49] Z. Zhao, R. Jing, Z. Shi, B. Zhao, Q. Ai, and G. Xing, "Efficacy of extracorporeal shockwave therapy for knee osteoarthritis: a randomized controlled trial," Journal of Surgical Research, vol. 185, no. 2, pp. 661–666, 2013.

[50] L. Zheng, Analysis of the short-term effect of the treatment on knee osteoarthritis by extracorporeal shock wave, Wannan Medical College, 2016.

[51] Z. Zhong, B. Liu, G. Liu et al., "A randomized controlled trial on the effects of low-dose extracorporeal shockwave therapy in patients with knee osteoarthritis," Archives of Physical Medicine and Rehabilitation, vol. 100, no. 9, pp. 1695–1702, 2019.

[52] Z. Y. Zhong, G. H. Liu, W. Q. Gu et al., "Clinical curative effect of radial extracorporeal shock wave therapy combined with muscle strengthening exercise on mild to moderate knee osteoarthritis," Geriatric Health Care, vol. 24, no. 5, pp. 490–493, 2018.

[53] A. Akinci, M. Al Shaker, M. H. Chang et al., "Predictive factors and clinical biomarkers for treatment in patients with chronic pain caused by osteoarthritis with a central sensitisation component," International Journal of Clinical Practice, vol. 70, no. 1, pp. 31–44, 2016.

[54] S. Ashford and J. Williard, "Osteoarthritis: a review," The Nurse Practitioner, vol. 39, no. 5, pp. 1–8, 2014.

[55] A. Litwic, M. H. Edwards, E. M. Dennison, and C. Cooper, "Epidemiology and burden of osteoarthritis," British Medical Bulletin, vol. 105, pp. 185–199, 2013.

[56] T. E. McAlindon, R. R. Bannuru, M. C. Sullivan et al., "OARSI guidelines for the non-surgical management of knee osteoarthritis," Osteoarthritis and Cartilage, vol. 22, no. 3, pp. 363–388, 2014.

[57] S. M. Hussain, D. W. Neilly, S. Baliga, S. Patil, and R. Meek, "Knee osteoarthritis: a review of management options," Scottish Medical Journal, vol. 61, no. 1, pp. 7–16, 2016.

[58] C. Sostres, C. J. Garullo, and A. Lanas, "Nonsteroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage," Arthritis Research & Therapy, vol. 15, Supplement 3, p. S3, 2013.

[59] E. M. Ilieva, M. Gonkova, I. Todorova, and R. Minchev, "New field of application of radial shock wave therapy - osteoarthritis," Annals of Physical and Rehabilitation Medicine, vol. 57, article e268, 2014.

[60] M. Imamura, S. Alamino, W. Hsing, F. Alfieri, C. Schmitz, and L. Battistella, "Radial extracorporeal shock wave therapy for disabling pain due to severe primary knee osteoarthritis," Journal of rehabilitation medicine, vol. 49, no. 1, pp. 54–62, 2017.

[61] J.-H. Kim, J.-Y. Kim, C.-M. Choi et al., "The dose-related effects of extracorporeal shock wave therapy for knee osteoarthritis," Annals of Rehabilitation Medicine, vol. 39, no. 4, pp. 616–623, 2015.

[62] J. Zwerver, C. Waugh, H. van der Worp, and A. Scott, "Can shockwave therapy improve tendon metabolism?", Advances in Experimental Medicine and Biology, vol. 920, pp. 275–281, 2016.

[63] J.-H. Cheng and C.-J. Wang, "Biological mechanism of shockwave in bone," International Journal of Surgery, vol. 24, no. Part B, pp. 143–146, 2015.

[64] C. J. Wang, J. H. Cheng, W. Y. Chou, S. L. Hsu, J. H. Chen, and C. Y. Huang, "Changes of articular cartilage and subchondral bone after extracorporeal shockwave therapy in osteoarthritis of the knee," International Journal of Medical Sciences, vol. 14, no. 3, pp. 213–223, 2017.

[65] Q. J. and C. He, "Extracorporeal shockwave therapy promotes chondrogenesis in cartilage tissue engineering: a hypothesis based on previous evidence," Medical Hypotheses, vol. 91, pp. 9–15, 2016.

[66] C.-J. Wang, F.-S. Wang, K. D. Yang et al., "Shock wave therapy induces neovascularization at the tendon–bone junction: a study in rabbits," Journal of Orthopaedic Research, vol. 21, no. 6, pp. 984–989, 2003.

[67] F. S. Wang, C. J. Wang, Y. J. Chen et al., "Ras induction of superoxide activates ERK-dependent angiogenic transcription factor HIF-1alpha and VEGF-A expression in shock wave-stimulated osteoblasts," The Journal of Biological Chemistry, vol. 279, no. 11, pp. 10331–10337, 2004.

[68] L. Martin, G. Giavaresi, M. Fini et al., "Effect of extracorporeal shock wave therapy on osteoblastlike cells," Clinical Orthopaedics and Related Research, vol. 413, pp. 269–280, 2003.

[69] C. V. B. de Gusmão, N. A. Batista, V. T. V. Lemes et al., "Effect of Low-Intensity Pulsed Ultrasound Stimulation, Extracorporeal Shockwaves and Radial Pressure Waves on Akt, BMP-2, ERK-2, FAK and TGF-β1 During Bone Healing in Rat Tibial Defects," Ultrasound in Medicine & Biology, vol. 45, no. 8, pp. 2140–2161, 2019.

[70] E. Suzuki, H. Ochiai-Shino, H. Aoki et al., "Akt activation is required for TGF-β1-induced osteoblast differentiation of MC3T3-E1 pre-osteoblasts," PLoS One, vol. 9, no. 12, article e112566, 2014.

[71] C. J. Wang, K. D. Yang, J. Y. Ko, C. C. Huang, H. Y. Huang, and F. S. Wang, "The effects of shockwave on bone healing and systemic concentrations of nitric oxide (NO), TGF-beta1, VEGF and BMP-2 in long bone non-unions," Nitric Oxide, vol. 20, no. 4, pp. 298–303, 2009.

[72] S.-L. Hsu, J.-J. Cheng, C.-J. Wang, J. Y. Ko, and C. H. Hsu, "Extracorporeal shockwave therapy enhances expression of Pdia-3 which is a key factor of the 1α,25-dihydroxyvitamin D 3 rapid membrane signaling pathway in treatment of early osteoarthritis of the knee," International Journal of Medical Sciences, vol. 14, no. 12, pp. 1220–1230, 2017.

[73] J. Chen, C. R. Dosier, J. H. Park et al., "Mineralization of three-dimensional osteoblast cultures is enhanced by the interaction of 1α,25-dihydroxyvitamin D3 and BMP2 via two specific vitamin D receptors," Journal of Tissue Engineering and Regenerative Medicine, vol. 10, no. 1, pp. 40–51, 2016.

[74] H. Zhang, Z. L. Li, F. Yang et al., "Radial shockwave treatment promotes human mesenchymal stem cell self-renewal and enhances cartilage healing," Stem Cell Research & Therapy, vol. 9, no. 1, p. 54, 2018.